David Kerstein
Impact in
-
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
Papers in
-
- Lung Cancer Treatments and Mutations 36
-
- Pharmacogenetics and Drug Metabolism 5
- Co-authors
- Corey Jay Langer (17 shared papers)Scott N. Gettinger (18 shared papers)D. Ross Camidge (22 shared papers)Frank G. Haluska (4 shared papers)Maximilian Johannes Hochmair (12 shared papers)Howard West (9 shared papers)Marcello Tiseo (13 shared papers)Rudolf Maria Huber (9 shared papers)
- Journals
- Annals of Oncology (13 papers)Journal of Thoracic Oncology (10 papers)Journal of Clinical Oncology (2 papers)Investigational New Drugs (2 papers)Lung Cancer (1 paper)
- Partner nations
- United StatesSpainSouth Korea
In The Last Decade
David Kerstein
38 papers receiving 2k citations
David Kerstein's Hit Papers
Peers
Comparison fields: 5 of 59
- Pulmonary and Respiratory Medicine 1.8k
- Pharmacology 86
- Toxicology 29
- Cancer Research 69
- Oncology 92
Countries citing papers authored by David Kerstein
This map shows the geographic impact of David Kerstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kerstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kerstein more than expected).
Fields of papers citing papers by David Kerstein
This network shows the impact of papers produced by David Kerstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kerstein. The network helps show where David Kerstein may publish in the future.
Co-authors
The 25 scholars most cited alongside David Kerstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 775 |
| 2 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Hit paper breakdown → | 2017 | 495 |
| 3 | Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial Hit paper breakdown → | 2016 | 301 |
| 4 | 2018 | 121 | |
| 5 | 2019 | 115 | |
| 6 | 2020 | 30 | |
| 7 | 2016 | 28 | |
| 8 | 2018 | 25 | |
| 9 | 2019 | 20 | |
| 10 | 2020 | 19 | |
| 11 | 2017 | 17 | |
| 12 | 2018 | 17 | |
| 13 | 2018 | 16 | |
| 14 | 2020 | 15 | |
| 15 | 2017 | 12 | |
| 16 | 2019 | 12 | |
| 17 | 2019 | 9 | |
| 18 | 2015 | 8 | |
| 19 | 2021 | 8 | |
| 20 | 2017 | 7 |
About David Kerstein
David Kerstein is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology, Pediatrics, Perinatology and Child Health, Economics and Econometrics and Nuclear Energy and Engineering, having authored 38 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (36 papers), Pharmacogenetics and Drug Metabolism (5 papers), Pharmaceutical studies and practices (3 papers) and Health Systems, Economic Evaluations, Quality of Life (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.8k citations), Pharmacology (86 citations), Toxicology (29 citations), Cancer Research (69 citations) and Oncology (92 citations). David Kerstein has collaborated with scholars based in United States, Spain and South Korea. Frequent co-authors include Corey Jay Langer, Scott N. Gettinger, D. Ross Camidge, Frank G. Haluska, Maximilian Johannes Hochmair, Howard West, Marcello Tiseo, Rudolf Maria Huber, Myung‐Ju Ahn and Dong‐Wan Kim. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Journal of Clinical Oncology, Investigational New Drugs and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.